Effect of the Dual 5α-Reductase Inhibitor Dutasteride on Markers of Tumor Regression in Prostate Cancer

    Gerald L. Andriole, Peter A. Humphrey, Paul S. Ray, M.E. Gleave, John Trachtenberg, Lynn N. Thomas, Catherine B. Lazier, Roger S. Rittmaster
    New to Dutasteride? There is a guide in the encyclopedia. Read the guide →
    Image
    Studysummary This letter to the editor addresses corrections related to an earlier study on the effect of the dual 5α-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer, but reports no new findings.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Discuss this study in the Community →

    Research cited in this study

    1 / 1 results